Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2015 May 11;14(7):1521–1531. doi: 10.1158/1535-7163.MCT-15-0100

Figure 5.

Figure 5

In vivo PTX resistance model development: (A) qPCR studies to assess MDR-1 and PKM-2 expression (B) Immunofluorescence of tumor tissues from Pg-P and PKM-2 expression in PBS treated and PTX treated animals. (C) Schematic representation of the dosing schedule adopted to develop the SKOV-3TR mouse model followed by nanoparticle treatment. (D) Effect of the combination of paclitaxel treatment and MDR1 and PKM2 silencing on growth of SKOV3TR tumors.